BiomX Inc.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 19, 2026
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows (unaudited)
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
| Six months ended | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (22,986) | (13,696) |
| Adjustments required to reconcile net loss for the period to net cash used in operating activities: | ||
| Depreciation | 5 | 528 |
| Stock-based compensation | 2,059 | 1,355 |
| Finance income, net | 382 | 247 |
| Revaluation of contingent consideration | - | 3 |
| Loss (income) from change in fair value of liability-classified warrants | 12,458 | (2,412) |
| Day one loss upon entering transaction | 5,226 | |
| Private Placement Warrants issuance cost | 186 | - |
| Gain from deconsolidation of subsidiary | (1,860) | - |
| Changes in balance of severance pay fund | 1 | - |
| Changes in operating assets and liabilities: | ||
| Loss from sale and disposal of fixed assets, net | - | 165 |
| Decrease (increase) in trade receivables | 511 | - |
| Other current assets | (1,419) | 1,096 |
| Trade accounts payable | 422 | 294 |
| Other accounts payable and current portion of lease liabilities | (1,572) | (2,404) |
| Net change in operating leases | 3 | 3 |
| Net cash used in operating activities | (6,584) | (14,821) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Investment in short term securities - net | (176) | - |
| Cash used in purchase of subsidiaries, net | (378) | - |
| Decrease in cash as a result of deconsolidation of subsidiary | (996) | - |
| Purchase of fixed assets | (2) | - |
| Proceeds from sale of property and equipment | - | 109 |
| Net cash provided by (used in) investing activities | (1,552) | 109 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Issuance of Common Stock under February 2025 SPA | - | 996 |
| February 2025 SPA issuance costs | - | (118) |
| Issuance of Common Warrants under February 2025 SPA | - | 4,531 |
| Issuance of Common Stock under Inducement Letter Agreements | - | 6,473 |
| Proceeds from related party loan | 656 | - |
| Proceeds from issuance of preferred share and warrants under January 2026 private placement, net of issuance costs | 2,622 | - |
| Short-term bank credit | 7 | - |
| Pre-Funded Warrants and Common Warrants exercise | - | 2 |
| Issuance of Common Stock under At the Market Sales Agreement, net of $39 issuance costs | 291 | - |
| Repayment of long-term loans | (48) | |
| Net cash provided by financing activities | 3,528 | 11,884 |
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (4,608) | (2,828) |
| Effect of exchange rate changes on cash and cash equivalents | - | 39 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 4,955 | 17,975 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | 347 | 15,186 |
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
| RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS | ||
|---|---|---|
| Cash and cash equivalents | 347 | 14,046 |
| Restricted cash | - | 1,140 |
| Total cash and cash equivalents and restricted cash | 347 | 15,186 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | 5 | 10 |
| Taxes paid | - | 3 |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES | ||
| Property and equipment purchases included in other accounts payable and trade accounts payable | - | 2 |
| Accrued Preferred dividends on Series Y Convertible Preferred Stock | 85 | - |
| Exercise of warrants into common stock | 16,785 | - |
| Conversion of Series Y Convertible Preferred Stock into common stock | 85 | - |
| Reclassification of embedded conversion derivative upon conversion of Series Y Convertible Preferred Stock | 7,818 | - |
The accompanying notes are an integral part of the condensed consolidated interim financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.